Chenge-Said J, Campeñacho-Asencio MÁ, Castellanos-Acuña MJ

Idioma: Español
Referencias bibliográficas: 20
Paginas: 262-264
Archivo PDF: 156.96 Kb.

FRAGMENTO

En 1950 las industrias Parke Davis en su búsqueda por encontrar el anestésico ideal que no causara depresión respiratoria ni cardiovascular y que además produjera analgesia sintetizan dos fármacos, la CI-395 (fenciclidina) y la CI-400 (clorhidrato de N-etil-fenilcicloxamina). Estos fármacos cumplían con los objetivos buscados pero tenían un gran defecto, causaban severos efectos psicodislépticos caracterizados por sueños «vividos» y alucinaciones. A pesar de lo anterior la fenciclidina se comercializó en Estados Unidos bajo el nombre de Sernyl^® y debido al uso recreacional excesivo (rápidamente se dio a conocer como «polvo de ángel») se detuvo su producción en 1978.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19:370-380.

2. Lois F, De Kock M. Something new about ketamine for pediatric anesthesia? Curr Opin Anaesthesiol. 2008;21:340-344.

3. Marland S, Ellerton J, Andolfatto G, Strapazzon G, Thomassen O, Brandner B, et al. Ketamine: use in anesthesia. CNS Neurosci Ther. 2013;19:381-389.

4. Fink AD, Ngai SH. Opiate receptor mediation of ketamine analgesia. Anestesiolghy. 1982;52:231-297.

5. Hirota K, Lambert DG. Ketamine: new uses for an old drug? Br J Anaesth. 2011;107:123-126.

6. Persson J. Ketamine in pain management. CNS Neurosci Ther. 2013;19:396-402.

7. Liu F, Patterson T, Sadovova N, Zhang X, Liu S, Zou X, et al. Ketamine-induced neuronal damage and altered n-methyl-d-aspartate receptor function in rat primary forebrain culture. Toxicol Sci. 2013;131:548-557.

8. Blonk MI, Koder BG, van den Bemt PM, Huygen FJ. Use of oral ketamine in chronic pain management: a review. Eur J Pain. 2010;14:466-472.

9. Sawynok J. Topical and peripheral ketamine as an analgesic. Anesth Analg. 2014;119:170-178.

10. Federe A, Parides M, Murrough J, Perez A, Morgan J, Saxena S, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder a randomized clinical trial. JAMA Psychiatry. 2014;71:681-688.

11. Joel S, Joselyn A, Cherian V, Nandhakumar A, Raju N, Kaliaperumal I. Low-dose ketamine infusion for labor analgesia: a double-blind, randomized, placebo controlled clinical trial. Saudi J Anaesth. 2014;8:6-10.

12. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939-946.

13. Kudoh A, Takahira Y, Katagai H, Takazawa T. Small dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002;95:114-118.

14. Romerol E. Depression and pain: does ketamine improve the quality of life of patients in chronic pain by targeting their mood? Anesthesiology. 2011;115:687-688.

15. Hirota K, Okawa H, Appadu BL, Grandy DK, Devi LA, Lambert DG. Stereoselective interaction of ketamine with recombinant m, k, and d opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology. 1999;90:174-182.

16. Welters ID, Hafer G, Menzebach A. Ketamine inhibits transcription factors activator protein 1 and nuclear factor-kappa B, interleukin-8 production, as well as CD11b and CD16 expression: studies in human leukocytes and leukocytic cell lines. Anesth Analg. 2010;110:934-941.

17. Mazar J, Rogachev B, Shaked G. Involvement of adenosine in the anti-inflammatory action of ketamine. Anesthesiology. 2005;102:1174-1181.

18. Welters D, Feurer M, Preiss V, Müller M, Scholz S, Kwapisz M, et al. Continuous S-(1)-ketamine administration during elective coronary artery bypass graft surgery attenuates proinflammatory cytokine response during and after cardiopulmonary bypass. Br J Anaesth. 2011;106:172-179.

19. Luo AT, Cao ZZ, Xiang Y, Zhang S, Qian CP, Fu C, et al. Ketamine attenuates the Na+-dependent Ca2+ overload in rabbit ventricular myocytes in vitro by inhibiting late Na+ and L-type Ca2+ currents. Acta Pharmacol Sin. 2015;36:1327-1336.

20. Ablin JN, Buskila D. Fibromyalgia syndrome--novel therapeutic targets. Maturitas. 2013;75:335-340.